Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Yanqiao Zhang et al.|Signal Transduction and Targeted Therapy|2025Cited by 20
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Sheng Hou, Kangsheng Gu et al.|Signal Transduction and Targeted Therapy|2025Cited by 8